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Aims.T oestablishtheprevalenceandtheeﬀectofthyroiddysfunctiononpregnancyoutcomesinAsian-Indianpopulation.Subjects
and Methods. The study cohort comprised of 483 consecutive pregnant women in the ﬁrst trimester attending the antenatal clinic
of a tertiary center in Mumbai, India. Thyroid hormone levels and thyroid peroxidase antibody were estimated. Patients with
thyroid dysfunction were assessed periodically or treated depending on the severity. Subjects were followed until delivery. Results.
The prevalence of hypothyroidism, Graves’ disease, gestational transient thyrotoxicosis, and thyroid autoimmunity (TAI) was
4.8% (n = 24), 0.6% (n = 3), 6.4 % (n = 31), and 12.4% (n = 60), respectively. Forty percent of the hypothyroid patients
did not have any high-risk characteristics. Hypothyroidism and TAI were associated with miscarriage (P = 0.02 and P = 0.001,
resp.). Conclusions. The prevalence of hypothyroidism (4.8%) and TAI (12.4%) is high. TAI and hypothyroidism were signiﬁcantly
associated with miscarriage.
1.Introduction
Pregnancy can be viewed as a state in which a combination
of events concurs to modify the thyroidal economy. There
is change in the level of thyroxine-binding globulin, total
thyroid-hormone level and change in the level of thyroid
stimulating hormone (TSH) during normal pregnancy [1].
Thyroid dysfunction (TD) may be overlooked in pregnancy
because of the nonspeciﬁc symptoms and hypermetabolic
state of normal pregnancy.
Thyroid dysfunction has varied impact on pregnancy
outcome.Theriskofmiscarriageisincreasedinautoimmune
thyroid disease. Severe maternal hypothyroidism can result
in irreversible neurological deﬁcit in the oﬀspring. Graves’
disease (GD) can lead to pregnancy loss as well as fetal
thyroid dysfunction.
The prevalence of hypothyroidism in pregnancy is
around 2.5% according to the Western literature [2]. The
prevalence of GD is around 0.1–0.4% and that of thyroid
autoimmunity (TAI) is around 5–10% [3]. Data on the
prevalence of TD during pregnancy is lacking in Asian-
Indian population. Hence, this study was planned to estab-
lish the prevalence of TD and to evaluate maternal outcome
in patients with TD.
2.MaterialandMethods
Study cohort was selected prospectively from consecutive
pregnant females in the ﬁrst trimester of pregnancy who
attended the antenatal clinic of a tertiary referral center,
in Mumbai, India, between January and April 2007. The
patients with documented history of hypothyroidism or thy-
rotoxicosis were excluded. The females were included irre-
spective of their gravida status (primigravida/multigravida),
and multiple pregnancies were also included.
Institutional ethics committee permission was obtained,
and subjects were recruited for the study after obtaining
written informed consent. They were subjected to clinical
evaluation with emphasis on the family history of thyroid
disorder and the obstetric history.2 Journal of Thyroid Research
Serum TSH and thyroid peroxidase antibody (TPOAb)
weredoneasinitialhormonalinvestigations,andthesubjects
were grouped based on the system proposed by Glinoer
[4]. The division into diﬀerent groups and their followup
are shown in Figure 1.S u b j e c t sw i t hT S H<2μIU/mL and
TPOAb negative (group 1) were considered as normal.
Patients with TSH 2–4μIU/mL, TPOAb positive (group 4)
and TSH > 4μIU/mL (group 5) were treated with thyroxine.
The aim of the treatment was to maintain TSH in the range
of 0.2–2μIU/mL. Once treatment was initiated or changed,
TSH was repeated at 6 weeks. Once TSH became normal, it
w a sr e p e a t e d2m o n t h l y .T P O A bt i t r e sw e r er e p e a t e de v e r y
trimester in those with baseline positivity.
In patients with TSH <0.1μIU/mL, TSH receptor anti-
body(TRAb)wasestimated.IfTRAbiselevated,diagnosisof
GD (group 6) was made. If TRAb was negative and β-human
chorionic gonadotropin (hCG) level is elevated, it was diag-
nosed as gestational transient thyrotoxicosis (GTT) (group
7). In GD, maternal thyroid functions were monitored by
free T3 (FT3)/free T4 (FT4) at monthly intervals. The aim
of the treatment was to maintain FT3/FT4 in the upper
quartile of normal nonpregnant range. Fetal monitoring of
the patient with GD was done using ultrasound monthly
from the 5th month of gestation focusing on fetal heart rate,
goiter, growth, and movements. For patients with GTT, FT3,
FT4, and TSH were done at 4 weekly intervals. All subjects
were followed till and attended to at the time of delivery.
TSH was estimated by the third generation chemilumi-
nescent immunometric assay (CLIA) (Immulite, analytical
sensitivity = 0.004μIU/mL, reference range = 0.4–4). FT3
(analytical sensitivity = 0.15pmol/L, reference range =
0.23–0.63) and FT4 (analytical sensitivity = 11.58pmol/L,
reference range = 10.3–24.45) were done by competitive
analogue-based immunoassay (Immulite). TPOAb (refer-
ence range < 35IU/mL, analytical sensitivity = 5IU/mL)and
β hCG were done by CLIA (Immulite) (reference ranges
vary according to gestational age). TRAb was done by ELISA
(Medizyme TRA, reference ranges: negative < 1IU/L, grey
zone = 1–1.5IU/L, positive > 1.5IU/L, analytical sensitivity
= 0.5IU/L).
Statistical analysis was done using SPSS Version 17 soft-
ware. The statistical signiﬁcance between means was calcu-
lated by Student’s t-test or Mann-Whitney U test whenever
appropriate. P value <0.05 was considered to be signiﬁcant.
3. Results
Four hundred and eighty-three subjects were recruited for
the study. The mean age of the subjects was 25.19 (±4.17)
years. The mean gestational age at presentation was 10.03
(±1.87) weeks. The prevalence of hypothyroidism was 4.8%
a n dt h a to fG Dw a s0 . 6 %( Figure 1). Goiter was present in
78 subjects (16.1%). Family history of thyroid disease was
presentin12subjects(2.5%),andTPOAbpositivitywasseen
in 60 subjects (12.4%). Of the 483 subjects, follow-up data is
available for 379 while the rest (21.5%) were lost to follow
up. The groupwise followup is as follows.
Group 1 (TSH 0.1–2μIU/mL, without TAI). The baseline
characteristics and pregnancy outcome are as given in
Tables 1and2,respectively.Thisgroupwastakenasreference
for comparison for other groups.
Group 2 (TSH 0.1–2μIU/mL with TAI). The baseline char-
acteristics were similar to group 1 except for the signiﬁcant
association with previous history of stillbirth (P = 0.042).
Followup revealed a signiﬁcant rise in TSH by 0.78μIU/mL
as pregnancy advanced. (P = 0.002). The titers of anti-TPO
antibodies decreased progressively towards the last trimester
by 85% (242 to 34IU/mL) (P = 0.043). Miscarriage was
3 times more common (26.3% versus 7.35%) in this group
of patients. There was no signiﬁcant association with other
pregnancy outcomes.
Group 3 (TSH 2–4μIU/mL without TAI). There was signif-
icant increase (by 0.25μIU/mL) in TSH (P = 0.029) and
signiﬁcant decrease in FT3/FT4 (P = 0.025 and 0.033, resp.)
at 6 months of pregnancy. Two patients (5.1%) had TSH
>4μIU/mL at 6 month followup. One of these patients had
stillbirth for which no speciﬁc cause was found.
Group 4 (TSH 2–4μIU/mL with TAI). These patients were
treated with thyroxine and followed up. There was no
signiﬁcant diﬀerence in baseline parameters or pregnancy
outcome in these patients.
Group 5 (TSH > 4μIU/mL). The women in this group were
o l d e rasc o m p ar edt oo t h e rgr o up s(P = 0.02). Forty percent
of these women did not have the high risk characteristics
required for targeted case ﬁnding as laid down by the
Endocrine Society guidelines [5].
The rate of miscarriage was 3 times higher in patients
with hypothyroidism (P = 0.02) (Table 2). Four patients
with hypothyroidism had miscarriage. Three patients were
overtly hypothyroid (TSH > 10μIU/mL). One patient (with
TSH 69μIU/mL) had abortion at 12 weeks of gestation, and
the other two proceeded to term without any signiﬁcant
complications. There was no signiﬁcant diﬀerence in still-
birth or premature delivery.
Group 6 (GD). All patients (n = 3) with GD presented
with classical features of thyrotoxicosis (palpitation, weight
loss, sweating, and tremor). One patient had abortion
soon after starting treatment, and another was lost to
follow up. One patient regularly followed up and required
Propylthiouracil throughout pregnancy in tapering doses.
TRAb titres reduced at third trimester (27IU/L to 14IU/L).
Shehadnormaldelivery.Thyroidhormonalevaluationofthe
baby was normal.
Group 7 (GTT). The prevalence of GTT was 6.4%. Thyroid
functions normalized in majority of the patients (70%) by
the ﬁrst followup (average gestational age = 14.4 weeks). In
the rest, it normalized by 18 weeks of gestation.
The comparison of baseline characteristics and preg-
nancy outcome between TPOAb-positive and -negativeJournal of Thyroid Research 3
Table 1: Baseline clinical characteristics in diﬀerent groups and comparison to subjects with group 1∗.
Group 1 Group 2 Group 3 Group 4 Group 5 Group 7
N = 323 N = 28 N = 59 N = 16 N = 23 N = 31
Age in years (mean ± SD) 25.09 ± 4.21 25 ± 4.65 24.42 ± 3.4 25.57 ± 3.3 29.37 ± 3.7 26.41 ± 4.9
P 1.00 1.00 0.622 0.022 0.544
H/O miscarriage N (%) 65 (20.1) 6 (21.4) 13 (21.6.) 2 (12.5) 5 (21.4) 7 (22.5)
P 0.620 0.728 0.513 0.712 0.726
H/O stillbirth N (%) 15 (4.6) 4 (14.3) 6 (10) 0 (0) 1 (4.2) 0 (0)
P 0.042 0.087 0.551 0.823 0.231
Infertility treatment N (%) 8 (2.4) 1 (3.6) 1 (1.7) 0 (0) 1 (4.2) 0 (0)
P 0.582 0.793 0.592 0.761 0.548
Family history N (%) 6 (1.9) 0 (0) 1 (1.7) 0 (0) 2 (8.9) 1 (3.2)
P 0.631 0.704 0.791 0.324 0.435
Goiter N (%) 52 (16.1) 5 (17.9) 5 (8.3) 4 (25) 5 (21.4) 4 (12.9)
P 0.587 0.130 0.155 0.241 0.451
∗Patients with GD (Group 6) not included as the number is small (N = 3).
Table 2: Pregnancy outcome in various groups∗.
Group Number Miscarriage n (%) Stillbirth n (%) Premature delivery (<37 weeks) n (%) Full-term delivery n (%)
Group 1 272 20 (7.35) 4 (1.47) 14 (5.14) 234 (86.02.)
Group 2 19 5 (26.31) 1 (5.3) 2 (10.6) 11 (57.9)
P 0.001 $NS NS 0.034
Group 3 40 3 (7.5.) 2 (5.0) 4 (10.0) 31 (77.5)
P NS NS NS NS
Group 4 7 1 (14.3) 0 (0) 1 (14.3) 5 (71..4)
P NS NS NS NS
Group 5 17 4 (23.5) 0 (0) 1 (5.9) 12 (70. 6)
P 0.02 NS NS NS
Group 7 22 1 (4.5) 0 (0) 2 (9.1) 19 (86.36)
P NS NS NS NS
$NS: nonsigniﬁcant.
∗Patients with GD (Group 6) not included as the number is small (N = 2).
Table 3: Comparison between TPOAb-positive and -negative women#.
Variables TPOAb + (n = 33) TPOAb − (n = 322) P value
Age (yrs) 25.77 ± 4.24 25.09 ± 2.54 0.372
Goiter (%) 23.8 15.2 0.301
Family history (%) 3.03 4.23 0.897
Past H/O miscarriages (%) 19.93 20.6 0.892
Infertility treatment (%) 2.56 2.46 0.580
TSH (μIU/mL) 3.88 ± 1.2 1.24 ± 1.2 <0.001
Mean TPO titers (IU/mL) 352.92 ± 335.6 14.71 ± 5.2 <0.001
Any complication∗ (%) 19.04 12.8 0.463
Miscarriage (%) 24.24 7.76 0.005
Preterm delivery (%) 9.09 5.9 0.730
Stillbirth (%) 3.03 1.42 0.124
Full term delivery (%) 66.7 84.16 0.023
Birth weight (kg) 2.7 ± 0.63 2.6 ± 0.52 0.590
∗Complication includes miscarriages, preterm delivery, pregnancy-induced hypertension, gestational diabetes mellitus, and intrauterine death.
#Baseline data of patients who are lost to follow up is not shown. Patients in Group 6 and 7 are excluded.4 Journal of Thyroid Research
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N = 31(6.4%)
Figure 1: Classiﬁcation into various groups based on TSH and antibody status. TSH: Thyroid stimulating hormone in μIU/mL, TPOAb:
thyroid peroxidase antibody. TRAb: TSH receptor antibody, hCG: human chorionic gonadotropin. TFT: thyroid function tests (FT3, FT4,
TSH, and TPO titres in those with positive TPOAb). ATD: antithyroid drugs.
women is given in Table 3. These women belong to groups
1, 2, 3, 4, and 5.
4. Discussion
The association between TD and adverse pregnancy out-
comes has been studied earlier in western countries [6–
9]. This has scarcely been studied in Indian population
except two studies which looked at the prevalence of
hypothyroidism in pregnant females [10, 11].
The mean age at presentation is lower (25.19 ± 4.17
years) compared to Western studies, namely, 27 ± 6y e a r s
[12], 29 ± 5y e a r s[ 9] reﬂecting early marriage and early
conception prevalent in India. The mean gestational age at
presentation was 10.03 (±1.87) weeks indicating that most
of the pregnant women in India do not visit the antenatal
clinic during the ﬁrst 8 weeks of gestation.
Our study demonstrates a higher incidence of hypothy-
roidism and TAI. The prevalence of hypothyroidism in this
cohort is 4.8% which is higher than that in the western
literature (2.5% [13], 2.6% [12]) and a previous Indian
study (3.69% [11]). The higher prevalence in our study
could be due to the higher prevalence of TAI in our cohort
(12.4%versus6.5%[13]and8%[12]).Studiessystematically
assessing the prevalence of TAI during pregnancy, however,
have not been reported from India. Iodine deﬁciency could
be a contributory cause, but this information cannot be
generated from our study as urinary iodine estimation was
not done. The percentage of households consuming iodised
saltinIndiaaspertheIodineNetworkGlobalscorecard2010
is 51% [14].
In the present study, the probable reason for higher
miscarriage in patients with hypothyroidism was that they
might have had undetected hypothyroidism at conception,
and the treatment might have been insuﬃcient to restore
euthyroidism. The higher age (mean = 29 years) could also
have contributed to miscarriage. Abalovich et al. [9] showed
that untreated hypothyroidism, subclinical, or overt, at the
time of conception is associated with miscarriage rate of
31.4% compared with 4% in euthyroid subjects at concep-
tion. The prevalence of stillbirth and premature delivery was
not signiﬁcantly higher than that in our hypothyroid patient
population probably due to the adequate treatment given to
the patients to maintain euthyroid state.
The miscarriage rate was 3 times more common in
subjects with TAI (7.35 versus 26.5%) in our cohort
(Table 3). The association has previously been established by
v a r i o u ss t u d i e s[ 6–8, 13]. TAI may be viewed as a marker of
generalizedimmuneimbalancethatwillexplaintherejection
of fetal graft [15]. Presence of TAI could be associated with
a subtle thyroid hormone deﬁciency, due to the reduced
functional reserve characteristic of chronic thyroiditis [15].
Women with thyroid antibodies tend to become pregnant
at an average 3-4 years later and are, therefore, more prone
to pregnancy loss. In our cohort, the relatively higher age in
the patients with miscarriage might also have contributed to
pregnancy loss.
In subjects with TSH <2μIU/mL with TAI, history of
stillbirth was signiﬁcantly higher suggesting the association
between thyroid autoimmunity and pregnancy loss. Some
of the previous studies showed higher number of premature
deliveries in women with TAI compared to normal women
[9, 13]. Our study did not reveal such association.
T h y r o i df u n c t i o ni ns u b j e c t sw i t hT S H2 – 4 μIU/mL
withoutTAIshowedsigniﬁcantincreaseinTSHanddecrease
in FT3 and FT4 at 6 months compared to baseline. TheJournal of Thyroid Research 5
signiﬁcant decline in thyroid functions for this subgroup
at the latter half of pregnancy may justify thyroxine sup-
plementation and regular monitoring (though presently
not recommended) in this subgroup in the second half of
gestation.
Patients with TSH 2–4μIU/mL with TPOAb positivity
were treated with thyroxine. The rationale for opting for
treatment in these patients is the fact that despite the TSH
downregulation in the ﬁrst trimester by hCG, TSH level
is in the upper half of normal, and there would be a
tendency for progressive decline in thyroid function since
they have TAI [16]. Though it is recommended to perform
FT4estimationbeforeinitiatingtreatment(inlow-normalor
low FT4) in this subset of individuals, the lack of trimester-
speciﬁc normal values for FT4 and the inherent problems
with FT4 assay made us focus on serum TSH as the marker
for initiating and monitoring treatment. There was no
signiﬁcantdiﬀerenceinthe pregnancy outcomein this group
of patients compared to normal. This may be due to the
smaller number of patients in this subset and the treatment
given to these patients.
The prevalence of GTT in the cohort was 6.4%. In India,
the prevalence of GTT has not been assessed previously.
The prevalence of GTT varies from 2-3% in the Western
literature [17] .T h ep r e v a l e n c eo fG Di nt h i sc o h o r ti s0 . 6 % ,
higher than that published in the Western literature (0.2–
0.4%) [18]. Further conclusions could not be derived since
the sample size was small.
Our data gives a prevalence of thyroid dysfunction in
subjects attending a tertiary care centre in Western India
which can be generalized to population in the same setting
in other parts of India. One limitation of our study was
that 21% of subjects were lost to follow up. The Endocrine
Society guidelines suggest that universal thyroid screening
during pregnancy cannot be recommended, and aggressive
case ﬁnding is recommended in speciﬁc subsets of subjects
[5]. But recent studies have shown that targeted case ﬁnding
will miss around 30–50% cases of hypothyroidism and/or
TAI [12, 19]. This is similar to the present study in which
40% of the hypothyroid and 45% of TPOAb positive patients
did not have high-risk characteristics. Approximately 60% of
the hypothyroid or TPOAb positive pregnant women could
have been missed by targeted case ﬁnding.
5. Conclusions
The prevalence of hypothyroidism (4.8%) and TAI (12.4%)
was found to be high in the present study. TAI and
hypothyroidism were found to be signiﬁcantly associated
with miscarriage.
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